GC Green Cross MS Introduces COVID-19 Immunity Formation Measurement Kit in Korea

MOU for Domestic Sales Cooperation of T-Cell Diagnostic Kits with UK Oxford Immunotec

On the 29th, at the GC녹십자엠에스 headquarters in Yongin, Gyeonggi-do, (from left) Lee Seung-bok, CEO of Mesdia, Ahn Eun-eok, CEO of GC녹십자엠에스, and Lee Soo-jong, head of Oxford Immunotec Korea, are taking a commemorative photo after signing a domestic sales agreement. (Photo by GC녹십자엠에스)

[Asia Economy Reporter Jihee Kim] GC Green Cross MS is introducing a COVID-19 virus immunity formation measurement kit to the domestic market.

GC Green Cross MS announced on the 1st that it signed a memorandum of understanding (MOU) on the 29th of last month at its headquarters in Yongin, Gyeonggi Province, with UK-based diagnostic company Oxford Immunotec and in vitro diagnostic product specialist Mesdia for domestic sales cooperation of the COVID-19 T-cell diagnostic kit. According to this agreement, GC Green Cross MS and Mesdia will be responsible for domestic sales and import of Oxford Immunotec products, respectively. Oxford Immunotec Korea will provide overall support for sales, marketing, and technical aspects of the products.

Using Oxford Immunotec's ‘T-SPOT’ technology, the ‘T-SPOT Discovery SARS-CoV-2 kit’ measures the intensity of T-cell expression against the COVID-19 virus in the blood to determine immunity formation. It is optimized for measuring immunity formation following large-scale COVID-19 vaccination and is used in the UK for COVID-19 vaccine development and clinical evaluation.

Aneok Ahn, CEO of GC Green Cross MS, said, “We actively decided to introduce the product domestically, anticipating a surge in demand coinciding with the start of domestic COVID-19 vaccinations. Along with the existing six types of COVID-19 diagnostic kits and the GENEDIA W COVID-19 Ag kit currently undergoing domestic approval, we will challenge the expansion of the COVID-19 diagnostic kit market with this product.”

Meanwhile, Oxford Immunotec was selected last October by the UK government’s vaccine task force as the sole supplier of T-cell diagnostic tests to evaluate the immunogenicity of COVID-19 vaccines.

This content was produced with the assistance of AI translation services.